At the halfway point of the process, the Company received notice from the FDA that additional information regarding the PMA is required for the continuation of a substantive review. This request, which is not unique to the Breakthrough Device Program, places the application file on hold for approximately 4 to 6 months while the Company addresses the FDA's questions.
any thoughts on what a substantive review would mean?
also what does the context of "not unique" imply?
thanks
At the halfway point of the process, the Company received notice...
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.63 |
Change
0.160(6.48%) |
Mkt cap ! $179.0M | |||
| Open | High | Low | Value | Volume |
| $2.54 | $2.64 | $2.54 | $874.2K | 336.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3056 | $2.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.63 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |